253 related articles for article (PubMed ID: 18451000)
1. Did CATIE influence antipsychotic use?
Citrome L; Jaffe A; Martello D; Allingham B; Levine J
Psychiatr Serv; 2008 May; 59(5):476. PubMed ID: 18451000
[No Abstract] [Full Text] [Related]
2. What CATIE found: results from the schizophrenia trial.
Swartz MS; Stroup TS; McEvoy JP; Davis SM; Rosenheck RA; Keefe RS; Hsiao JK; Lieberman JA
Psychiatr Serv; 2008 May; 59(5):500-6. PubMed ID: 18451005
[TBL] [Abstract][Full Text] [Related]
3. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
Park T; Kuntz KM
Value Health; 2014 Jun; 17(4):310-9. PubMed ID: 24968989
[TBL] [Abstract][Full Text] [Related]
5. Onset of action of atypical and typical antipsychotics in the treatment of adolescent schizophrenic psychoses.
Zedkova I; Dudova I; Urbanek T; Hrdlicka M
Neuro Endocrinol Lett; 2011; 32(5):667-70. PubMed ID: 22167144
[TBL] [Abstract][Full Text] [Related]
6. Lessons to be learned from CATIE and CUtLASS.
Sutton BJ
Psychiatr Serv; 2008 May; 59(5):473. PubMed ID: 18450999
[No Abstract] [Full Text] [Related]
7. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.
Montgomery JH; Byerly M; Carmody T; Li B; Miller DR; Varghese F; Holland R
Control Clin Trials; 2004 Dec; 25(6):598-612. PubMed ID: 15588746
[TBL] [Abstract][Full Text] [Related]
8. Resource utilization in a Canadian national study of people with schizophrenia and related psychotic disorders.
Kopala L; Smith G; Malla A; Williams R; Love L; Talling D; Balshaw R
Acta Psychiatr Scand Suppl; 2006; (430):29-39. PubMed ID: 16542323
[TBL] [Abstract][Full Text] [Related]
9. Schizophrenia, VI: Treatments.
Lieberman JA; Stroup TS
Am J Psychiatry; 2003 Oct; 160(10):1748. PubMed ID: 14514482
[No Abstract] [Full Text] [Related]
10. Interpreting the results of the CATIE study.
Pandiani JA; Banks SM
Psychiatr Serv; 2006 Jan; 57(1):140-1. PubMed ID: 16399981
[No Abstract] [Full Text] [Related]
11. Impact of side-effects of atypical antipsychotics on non-compliance, relapse and cost.
Mortimer A; Williams P; Meddis D
J Int Med Res; 2003; 31(3):188-96. PubMed ID: 12870371
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of antipsychotics in the elderly: a focus on atypicals.
Finkel S
J Am Geriatr Soc; 2004 Dec; 52(12 Suppl):S258-65. PubMed ID: 15541166
[No Abstract] [Full Text] [Related]
13. The CATIE schizophrenia effectiveness trial.
Delisi LE; Nasrallah HA
Schizophr Res; 2005 Dec; 80(1):v-vi. PubMed ID: 16291292
[No Abstract] [Full Text] [Related]
14. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis.
San L; Arranz B; Perez V; Safont G; Corripio I; Ramirez N; Dueñas R; Alvarez E
Psychiatry Res; 2012 Dec; 200(2-3):693-701. PubMed ID: 22954905
[TBL] [Abstract][Full Text] [Related]
15. Switching antipsychotic medications: not enough, too often, or just right?
Weiden PJ
Am J Psychiatry; 2011 Sep; 168(9):882-4. PubMed ID: 21890800
[No Abstract] [Full Text] [Related]
16. [Current pharmacotherapy of schizophrenia].
Bitter I
Orv Hetil; 2004 Jan; 145(3):105-9. PubMed ID: 15027331
[TBL] [Abstract][Full Text] [Related]
17. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
Swartz MS; Perkins DO; Stroup TS; Davis SM; Capuano G; Rosenheck RA; Reimherr F; McGee MF; Keefe RS; McEvoy JP; Hsiao JK; Lieberman JA;
Am J Psychiatry; 2007 Mar; 164(3):428-36. PubMed ID: 17329467
[TBL] [Abstract][Full Text] [Related]
18. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
[TBL] [Abstract][Full Text] [Related]
19. Comments to the editor on "Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model".
Clewell JD; Baker RW
Value Health; 2005; 8(2):175-6. PubMed ID: 15804326
[No Abstract] [Full Text] [Related]
20. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
